TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage: a Multicenter Randomized Trial
Brief Summary: The aim of our study is to assess three anticoagulation strategies for intermittent hemodialysis(IHD) in patients at risk of hemorrhage. A registry of consecutive hemodialysis patients with high risk of hemorrhage was conducted at the Guangdong General Hospital, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, the Second Affiliated Hospital of Guangzhou Medicine University or Guangzhou Hospital of Chinese Medicine, between Sep 10, 2017 and June 30th,2018. In this multi-center prospective and randomized study, participants were randomly divided into three groups during IHD according to different anticoagulation, including with regular saline flushes, one stage regional citrate anticoagulation (RCA) and two-stage RCA.


Options:
A: Arm Label: LMWH arm; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: UFH arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): LMWH arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): UFH arm
B: Arm Label: Placebo without anticoagulation; Type: PLACEBO_COMPARATOR; Interventions: Drug: catheter induced thromboprophylaxis | Arm Label: Low Dose Direct Oral Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: catheter induced thromboprophylaxis | Intervention Type: DRUG; Name: catheter induced thromboprophylaxis; Assigned to Arm(s): Low Dose Direct Oral Anticoagulation, Placebo without anticoagulation
C: Arm Label: saline flushes; Type: PLACEBO_COMPARATOR; Interventions: Drug: two stage regional citrate | Arm Label: one stage regional citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: one stage regional citrate | Arm Label: two stage regional citrate; Type: EXPERIMENTAL; Interventions: Drug: two stage regional citrate, Drug: one stage regional citrate | Intervention Type: DRUG; Name: two stage regional citrate; Assigned to Arm(s): saline flushes, two stage regional citrate | Intervention Type: DRUG; Name: one stage regional citrate; Assigned to Arm(s): one stage regional citrate, two stage regional citrate
D: Arm Label: Heparin free dialysis standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Heparin free dialysis technique | Arm Label: Heparin free dialysis with Evodial; Type: EXPERIMENTAL; Interventions: Device: Evodial | Intervention Type: OTHER; Name: Heparin free dialysis technique; Assigned to Arm(s): Heparin free dialysis standard of care | Intervention Type: DEVICE; Name: Evodial; Assigned to Arm(s): Heparin free dialysis with Evodial

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.


Options:
A: Arm Label: NB-UVB; Type: EXPERIMENTAL; Interventions: Device: Narrow band UVB phototherapy , long wave UVA phototherapy | Arm Label: UVA; Type: PLACEBO_COMPARATOR; Interventions: Device: Narrow band UVB phototherapy , long wave UVA phototherapy | Intervention Type: DEVICE; Name: Narrow band UVB phototherapy , long wave UVA phototherapy; Assigned to Arm(s): NB-UVB, UVA
B: Arm Label: CR845 0.5mcg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CR845 0.5 mcg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CR845 0.5 mcg/kg; Assigned to Arm(s): CR845 0.5mcg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sarna Lotion; Type: EXPERIMENTAL; Interventions: Drug: Sarna | Arm Label: Placebo Cetaphil lotion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cetaphil | Intervention Type: DRUG; Name: Sarna; Assigned to Arm(s): Sarna Lotion | Intervention Type: DRUG; Name: Cetaphil; Assigned to Arm(s): Placebo Cetaphil lotion
D: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): montelukast | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Libera Efficacy 2 Cycles at Home Study
Brief Summary: Clearblue Connected Ovulation Test System (COTS) has been designed for home use by women who are either planning or trying for a pregnancy. This study will determine the difference in pregnancy rate of female volunteers seeking to get pregnant who use COTS in comparison to those not using an ovulation product to assist with conception.


Options:
A: Arm Label: every other day; Type: EXPERIMENTAL; Interventions: Other: health educational video | Arm Label: fertile window; Type: EXPERIMENTAL; Interventions: Other: health educational video | Arm Label: CG; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health educational video; Assigned to Arm(s): every other day, fertile window
B: Arm Label: COTS; Type: ACTIVE_COMPARATOR; Interventions: Device: Clearblue Connected Ovulation Test System | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Clearblue Connected Ovulation Test System; Assigned to Arm(s): COTS
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Preconception advice | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Instruction in the Creighton Model Fertility Care System | Intervention Type: BEHAVIORAL; Name: Instruction in the Creighton Model Fertility Care System; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Preconception advice; Assigned to Arm(s): 1
D: Arm Label: Active; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Strategies to Improve General Practitioner-nurse Collaboration and Communication in Regard to Hospital Admissions of Nursing Home Residents.
Brief Summary: Previously,six measures were developed for a better collaboration of general practitioners and nurses in nursing homes in a qualitative multistep bottom-up process. These measures, summarised as the interprof ACT intervention, shall improve the flow of information and the communication between the involved parties and lead to more transparency and effectiveness regarding treatment decisions of nursing home residents.The major aim of this trial is to examine the clinical effectiveness of interprof ACT. The main hypothesis is that implementation of interprof ACT reduces the cumulative incidence of hospitalisations of nursing home residents within 12 months from 50% to 35% (15% absolute reduction).


Options:
A: Arm Label: Multi-disciplinary wound care team; Type: EXPERIMENTAL; Interventions: Other: Exposure to multi-disciplinary wound care team | Intervention Type: OTHER; Name: Exposure to multi-disciplinary wound care team; Assigned to Arm(s): Multi-disciplinary wound care team
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: OptiMEDs | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: OptiMEDs; Assigned to Arm(s): Intervention
C: Arm Label: normal care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: telemedicine | Intervention Type: PROCEDURE; Name: telemedicine; Assigned to Arm(s): telemedicine
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional Group; Type: EXPERIMENTAL; Interventions: Procedure: interprof ACT measures | Intervention Type: PROCEDURE; Name: interprof ACT measures; Assigned to Arm(s): Interventional Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: mDOT: A Pilot Study of Video Directly Observed Therapy for Immunosuppressant Adherence in Adult Kidney Transplant Recipients
Brief Summary: The investigators are interested in whether or not the use of a mobile health (mHealth) application increases the rate of immunosuppression medication adherence among adult kidney transplant recipients. The investigators aim to test this by randomly assigning transplant recipients to the intervention (use of an mHealth app to manage and track their immunosuppression regimen) or control arm (standard of care) upon discharge from their initial transplant hospitalization, and tracking medication adherence over time. The study population will be approximately 50 adult kidney transplant recipients at the Johns Hopkins Hospital.


Options:
A: Arm Label: With Med-O-Wheel™; Type: N/A; Interventions: N/A | Arm Label: With out Med-O-Wheel™; Type: N/A; Interventions: N/A
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: mHealth Intervention | Intervention Type: OTHER; Name: mHealth Intervention; Assigned to Arm(s): mHealth Intervention
C: Arm Label: standard of care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: remote home monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: remote home monitoring | Intervention Type: BEHAVIORAL; Name: remote home monitoring; Assigned to Arm(s): remote home monitoring
D: Arm Label: Tacrolimus twice-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus twice daily | Arm Label: Envarsus XR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Envarsus XR | Intervention Type: DRUG; Name: Envarsus XR; Assigned to Arm(s): Envarsus XR | Intervention Type: DRUG; Name: Tacrolimus twice daily; Assigned to Arm(s): Tacrolimus twice-daily

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Preventive Efficacy of an Algorithm Taking Place After Suicide Attempts Among Attempters Admitted to Hospital in the French Overseas Territories
Brief Summary: In France, suicide behaviours are a major public health concern that triggered the creation in 2013 of a National Observatory of Suicide. In continental France, the "Algos" protocol was found to be effective for the prevention of suicide attempts reiterations. This protocol is based on a procedure that keeps telephone and postal contacts with the suicide attempter and allows, via an algorithm, to assess the risk of suicide attempt recurrence, in order to intervene if necessary. Nevertheless, Algos does not involve primary care health practitioners, who could add a substantial additional efficacy, especially if they intervene downstream and in supplement to Algos. In addition, this kind of protocol has never been evaluated in the French overseas territories.


Options:
A: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: APSOM vs Control | Arm Label: APSOM; Type: OTHER; Interventions: Other: APSOM vs Control | Intervention Type: OTHER; Name: APSOM vs Control; Assigned to Arm(s): APSOM, Control
D: Arm Label: Escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Preventive Efficacy of an Algorithm Taking Place After Suicide Attempts Among Attempters Admitted to Hospital in the French Overseas Territories
Brief Summary: In France, suicide behaviours are a major public health concern that triggered the creation in 2013 of a National Observatory of Suicide. In continental France, the "Algos" protocol was found to be effective for the prevention of suicide attempts reiterations. This protocol is based on a procedure that keeps telephone and postal contacts with the suicide attempter and allows, via an algorithm, to assess the risk of suicide attempt recurrence, in order to intervene if necessary. Nevertheless, Algos does not involve primary care health practitioners, who could add a substantial additional efficacy, especially if they intervene downstream and in supplement to Algos. In addition, this kind of protocol has never been evaluated in the French overseas territories.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: APSOM vs Control | Arm Label: APSOM; Type: OTHER; Interventions: Other: APSOM vs Control | Intervention Type: OTHER; Name: APSOM vs Control; Assigned to Arm(s): APSOM, Control
B: Arm Label: Cognitive Analytic Informed Brief Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive analytic informed brief therapy | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive analytic informed brief therapy; Assigned to Arm(s): Cognitive Analytic Informed Brief Therapy
C: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: Dialectical behavior therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical behavior therapy | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Fluoxetine
D: Arm Label: Brief Admission; Type: EXPERIMENTAL; Interventions: Other: Brief Admission | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Brief Admission; Assigned to Arm(s): Brief Admission

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Preventive Efficacy of an Algorithm Taking Place After Suicide Attempts Among Attempters Admitted to Hospital in the French Overseas Territories
Brief Summary: In France, suicide behaviours are a major public health concern that triggered the creation in 2013 of a National Observatory of Suicide. In continental France, the "Algos" protocol was found to be effective for the prevention of suicide attempts reiterations. This protocol is based on a procedure that keeps telephone and postal contacts with the suicide attempter and allows, via an algorithm, to assess the risk of suicide attempt recurrence, in order to intervene if necessary. Nevertheless, Algos does not involve primary care health practitioners, who could add a substantial additional efficacy, especially if they intervene downstream and in supplement to Algos. In addition, this kind of protocol has never been evaluated in the French overseas territories.


Options:
A: Arm Label: S-DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Standard dialectical behavior therapy (SDBT) | Arm Label: DBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual DBT with no DBT group sessions (DBT-I) | Arm Label: DBT-S; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Skills DBT with no DBT individual sessions (DBT-S) | Intervention Type: BEHAVIORAL; Name: Standard dialectical behavior therapy (SDBT); Assigned to Arm(s): S-DBT | Intervention Type: BEHAVIORAL; Name: Individual DBT with no DBT group sessions (DBT-I); Assigned to Arm(s): DBT-I | Intervention Type: BEHAVIORAL; Name: Group Skills DBT with no DBT individual sessions (DBT-S); Assigned to Arm(s): DBT-S
B: Arm Label: F-SPS Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: F-SPS+UC | Arm Label: Enhanced Usual Care (EUC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EUC | Intervention Type: BEHAVIORAL; Name: F-SPS+UC; Assigned to Arm(s): F-SPS Intervention | Intervention Type: BEHAVIORAL; Name: EUC; Assigned to Arm(s): Enhanced Usual Care (EUC)
C: Arm Label: Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): Care Management | Intervention Type: BEHAVIORAL; Name: Skills Training; Assigned to Arm(s): Skills Training | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: APSOM vs Control | Arm Label: APSOM; Type: OTHER; Interventions: Other: APSOM vs Control | Intervention Type: OTHER; Name: APSOM vs Control; Assigned to Arm(s): APSOM, Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial: Single Versus Multiple-infusion Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Brief Summary: Fecal microbiota transplantation (FMT) is acknowledged as a highly effective treatment for recurrent Clostridium difficile infection (CDI). Usually single fecal infusion achieves satisfactory cure rates of recurrent CDI). However, several retrospective studies show that severe clinical picture of recurrent CDI is a risk factor for the failure of single-infusion FMT, suggesting that multiple fecal infusions are required to cure this condition.

This is an open-label randomized clinical trial aiming to assess if multiple-infusion FMT is more effective than single-infusion FMT in curing severe CDI


Options:
A: Arm Label: Colonoscopy; Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Arm Label: Nasogastric Tube (NGT); Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Intervention Type: DRUG; Name: Fecal Microbiota Transplant (FMT); Assigned to Arm(s): Colonoscopy, Nasogastric Tube (NGT)
B: Arm Label: Multiple-infusion FMT; Type: EXPERIMENTAL; Interventions: Drug: Vancomycin (before randomization), Biological: multiple-infusion FMT | Arm Label: Single-infusion FMT; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single-infusion FMT, Drug: Vancomycin (before randomization) | Intervention Type: BIOLOGICAL; Name: Single-infusion FMT; Assigned to Arm(s): Single-infusion FMT | Intervention Type: DRUG; Name: Vancomycin (before randomization); Assigned to Arm(s): Multiple-infusion FMT, Single-infusion FMT | Intervention Type: BIOLOGICAL; Name: multiple-infusion FMT; Assigned to Arm(s): Multiple-infusion FMT
C: Arm Label: Fecal Microbiota Transplantation; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fecal Microbiota Transplantation | Arm Label: Sham Fecal Microbiota Transplantation; Type: SHAM_COMPARATOR; Interventions: Biological: Sham Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplantation; Assigned to Arm(s): Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Sham Fecal Microbiota Transplantation; Assigned to Arm(s): Sham Fecal Microbiota Transplantation
D: Arm Label: Recurrent CDI FMT; Type: EXPERIMENTAL; Interventions: Biological: faecal human microbiota transplant (FMT) | Arm Label: Primary CDI antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin or Fidaxomicin | Arm Label: Primary CDI FMT; Type: EXPERIMENTAL; Interventions: Biological: faecal human microbiota transplant (FMT) | Intervention Type: BIOLOGICAL; Name: faecal human microbiota transplant (FMT); Assigned to Arm(s): Primary CDI FMT, Recurrent CDI FMT | Intervention Type: DRUG; Name: Vancomycin or Fidaxomicin; Assigned to Arm(s): Primary CDI antibiotic

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Comparison of Effectiveness of Facemask Preoxygenation and Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in Bariatric Patients Undergoing General Anaesthesia
Brief Summary: The purpose of the study is to compare effectiveness of different methods of achieving pre-oxygenation in bariatric patients. The investigators intend to compare facemask pre-oxygenation with a high-flow humidified nasal oxygen.

The primary outcome measure of interest is time to desaturation to 92% or 18 minutes of apnoea.


Options:
A: Arm Label: Normoventilation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hyperventilation; Type: EXPERIMENTAL; Interventions: Procedure: Hyperventilation | Intervention Type: PROCEDURE; Name: Hyperventilation; Assigned to Arm(s): Hyperventilation
B: Arm Label: High flow oxygen therapy by nasal cannula; Type: EXPERIMENTAL; Interventions: Device: High flow oxygen therapy by nasal cannula. Optiflow® | Arm Label: Facial mask oxygenation in BIPAP ventilation; Type: ACTIVE_COMPARATOR; Interventions: Device: Facial mask oxygenation in BIPAP ventilation | Intervention Type: DEVICE; Name: High flow oxygen therapy by nasal cannula. Optiflow®; Assigned to Arm(s): High flow oxygen therapy by nasal cannula | Intervention Type: DEVICE; Name: Facial mask oxygenation in BIPAP ventilation; Assigned to Arm(s): Facial mask oxygenation in BIPAP ventilation
C: Arm Label: HFNC (High Flow Nasal Cannulae); Type: EXPERIMENTAL; Interventions: Device: HFNC | Arm Label: CON (control); Type: ACTIVE_COMPARATOR; Interventions: Device: CON (control) | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC (High Flow Nasal Cannulae) | Intervention Type: DEVICE; Name: CON (control); Assigned to Arm(s): CON (control)
D: Arm Label: Pre-oxygenation with a standard anaesthetic face mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard anaesthetic face mask | Arm Label: Pre-oxygenation using Optiflow and THRIVE technique; Type: EXPERIMENTAL; Interventions: Device: Optiflow and THRIVE technique | Intervention Type: DEVICE; Name: Optiflow and THRIVE technique; Assigned to Arm(s): Pre-oxygenation using Optiflow and THRIVE technique | Intervention Type: DEVICE; Name: Standard anaesthetic face mask; Assigned to Arm(s): Pre-oxygenation with a standard anaesthetic face mask

Answer: D